NCCN Task Force Report: Oral chemotherapy.
Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy.
Weingart
Saul N
SN
Dana-Farber Cancer Institute.
Brown
Elizabeth
E
Bach
Peter B
PB
Eng
Kirby
K
Johnson
Shirley A
SA
Kuzel
Timothy M
TM
Langbaum
Terry S
TS
Leedy
R Donald
RD
Muller
Raymond J
RJ
Newcomer
Lee N
LN
O'Brien
Susan
S
Reinke
Denise
D
Rubino
Mark
M
Saltz
Leonard
L
Walters
Ronald S
RS
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010349:Patient Compliance; D014481:United States
D000970:Antineoplastic Agents